Ganaxolone

Modify Date: 2024-01-02 10:16:09

Ganaxolone structure	Common Name	Ganaxolone
	CAS Number	38398-32-2	Molecular Weight	332.52000
	Density	1.036g/cm3	Boiling Point	434.8ºC at 760mmHg
	Molecular Formula	C₂₂H₃₆O₂	Melting Point	N/A
	MSDS	USA	Flash Point	185.4ºC

Use of Ganaxolone

Ganaxolone, also known as CCD 1042 and C1042, is a CNS-selective GABAA modulator that acts on well-characterized targets in the brain known to have anxiolytic and anticonvulsant effects. Ganaxolone protects against seizures in diverse animal models, including the pentylenetetrazol, 6 Hz and amygdala kindling models. Ganaxolone is a positive allosteric modulator of the action of the GABAA receptor and, unlike benzodiazepines, there does not appear to be tolerance to the anticonvulsant effects of ganaxolone.

Name	1-[(3R,5S,8R,9S,10S,13S,14S,17S)-3-hydroxy-3,10,13-trimethyl-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]ethanone
Synonym	More Synonyms

Density	1.036g/cm3
Boiling Point	434.8ºC at 760mmHg
Molecular Formula	C₂₂H₃₆O₂
Molecular Weight	332.52000
Flash Point	185.4ºC
Exact Mass	332.27200
PSA	37.30000
LogP	4.98530
Index of Refraction	1.517

Ganaxolone MSDS(Chinese)

Safety Phrases	22-24/25
RIDADR	NONH for all modes of transport
RTECS	TU4384700

Precursor 5
CAS#:55571-86-3 20,20-ethylened... CAS#:566-65-4 5α-Dihydroproge... CAS#:676-58-4 Methylmagnesium... CAS#:75-24-1 trimethylaluminum
CAS#:917-54-4 METHYLLITHIUM
DownStream 0

A quantitiative LC-MS/MS method for the measurement of arachidonic acid, prostanoids, endocannabinoids, N-acylethanolamines and steroids in human plasma.

J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 976-977 , 6-18, (2015)

Free arachidonic acid is functionally interlinked with different lipid signaling networks including those involving prostanoid pathways, the endocannabinoid system, N-acylethanolamines, as well as ste...

Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.

Xenobiotica 35 , 191-210, (2005)

The prediction of human pharmacokinetics is often based on in vivo preclinical pharmacokinetic data. However, to date, no clear guidance has been available about the relative ability of the major prec...

Endocannabinoid-mediated improvement on a test of aversive memory in a mouse model of fragile X syndrome.

Behav. Brain Res. 291 , 164-71, (2015)

Silencing the gene FMR1 in fragile X syndrome (FXS) with consequent loss of its protein product, FMRP, results in intellectual disability, hyperactivity, anxiety, seizure disorders, and autism-like be...

ccd-1042

Ganaxolone